Purpose This study aims to investigate the current state and sentiment of artificial intelligence (AI) training in North American anesthesiology residency programs, assessing existing AI education landscapes, identifying barriers to implementation, and understanding program directors’ expectations for AI’s impact on the field. Methods A cross-sectional survey targeted anesthesiology program directors across North America. The survey, conducted anonymously via Qualtrics, gauged their AI training offerings, sentiments towards AI’s influence, and familiarity with AI educational policies. Information on questionnaire development, administration, and data analysis was included. Results Of the 163 programs surveyed, 32 responded, yielding a response rate of 19.6%. A substantial 81% of responding program directors reported no current AI training. Despite this, 67% anticipate AI’s transformative impact. Only 19% currently offer AI/ML training. Standardized presentation of results with accompanying numerators and denominators were employed. Conclusion The findings reveal a significant gap between the recognition of AI’s importance and the current offering of training in anesthesiology residency programs. Barriers to implementation include resource constraints and time limitations, exacerbated by the pandemic. Overcoming these barriers and aligning positive sentiments with educational offerings is crucial for preparing future physicians for the AI-driven healthcare landscape. Implication Statement This study exposes a substantial gap between the positive anticipation of AI’s impact on anesthesiology and the current lack of training in North American residency programs. Recognizing this disparity is crucial for swiftly implementing comprehensive AI education, ensuring future anesthesiologists navigate healthcare’s evolving landscape adeptly. Disclosures The authors have no competing interests or financial interests to disclose. There was no funding associated with the completion of this study.
Current advances in the treatment of melanoma brain metastases through immune checkpoint blockade and targeted therapy has significantly improved outcomes and patient survival. Yet, half of all patients continue to die from brain metastases despite use of these therapies and the addition of localized therapies like surgery and stereotactic radiosurgery. Novel treatments are needed to improve the morbidity and mortality associated with melanoma brain metastases. We have identified the inflammatory myddosomal pathway as a novel potential target of therapy in melanoma brain metastases, with gross upregulation in both tumor tissue and tumor-infiltrating immune cells. These cells display upregulation in MYD88, IRAK-1, IRAK-4, and downstream mediators of inflammatory activation at both the gene and protein level. We have previously shown the ability of the oral IRAK-4 inhibitor emavusertib (CA-4948) to penetrate the blood brain barrier and inhibit the myddosomal pathway in metastatic melanoma and primary CNS lymphoma. In this study we further show the capacity for IRAK-4 inhibition with emavusertib to improve the therapeutic efficacy of anti-PD-1 immune checkpoint blockade in melanoma brain metastases. Emavusertib in combination with anti-PD-1 therapy results in improved tumor-infiltrating lymphocyte recruitment, decreased myeloid derived suppressor cell function, and upregulation of interferon γ signaling resulting in improved survival in aggressive mouse models of melanoma brain metastases. This work supports the development of combination strategies of emavusertib with immune checkpoint blockade in melanoma brain metastases.
Background: Recent data suggest that a subset of early stage melanoma patients may benefit from adjuvant immunotherapy. Objective: To identify findings in biopsy or surgical pathology reports associated with poor prognosis in patients diagnosed with stage I and II cutaneous melanoma. Methods: This was a retrospective cohort study of 68 stage I and II cutaneous melanoma patients treated at our institution from 2010 to 2022. Inclusion criteria were patients with stage I or II melanoma with both a biopsy and surgical pathology report. The primary outcome of the study was the prognostic value of biopsy findings on progression free survival (PFS). Kaplan-Meier and Cox-proportional hazards models were used to evaluate risk factors for progression. Results: Patients with ulceration on biopsy had a 16.1x greater risk of progression than those without ulceration [HR 16.1, 95% CI: 2.60-99.5]. Patients with absent lymphocytes on biopsy had a 9.5x greater risk of progressing compared to those with lymphocytes present [HR 9.45, 95% CI: 1.99-44.8]. Ulceration or absent TILs were associated with significantly worse PFS. Conclusions: Ulceration and absence of TILs on biopsy are associated with increased risk of progression in stage I and II melanoma patients.